What is Qualigen?
Qualigen is a biotechnology company dedicated to pioneering novel therapeutics for cancer and infectious diseases. Leveraging its proprietary nanoparticle coating technology, which has a proven track record in its FDA-approved FastPack® System used in diagnostics for over 15 years, the company is advancing a pipeline of promising treatments. Key candidates include ALAN (AS1411-GNP), a DNA-coated gold nanoparticle drug for various cancers with potential for minimal side effects; RAS-F3, a small molecule inhibitor targeting RAS oncogene protein-protein interactions crucial for blocking tumor formation in pancreatic, colorectal, and lung cancers; and STARS, a DNA/RNA-based device designed to remove targeted tumor-produced and viral compounds from circulating blood. The company operates an FDA and ISO Certified facility in Carlsbad, California, with its FastPack® product line distributed globally by commercial partner Sekisui Diagnostics, LLC.
How much funding has Qualigen raised?
Qualigen has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Qualigen?
The substantial late-stage funding positions Qualigen for accelerated development and potential commercialization of its innovative therapeutic candidates. This strategic investment is expected to fuel further clinical trials, enhance manufacturing capabilities, and expand market reach for its oncology and infectious disease treatments. The company's focus on leveraging its established diagnostic technology for therapeutic applications suggests a robust strategy for navigating the complex biotech landscape and achieving significant growth.
See full Qualigen company page
